Surgery Partners (SGRY) is at the center of a going private deal after HealthSpan Partners agreed to acquire a 61.24% stake in an all cash transaction valued at about US$5.7b.
The HealthSpan offer has sharply reset expectations for Surgery Partners, with the share price jumping to US$23.25 and a 1 day share price return of 47.62%. However, the 1 year total shareholder return of 1.53% and 5 year total shareholder return of 43% lower show that this sudden momentum follows a much weaker long term experience for investors.
Scan for other healthcare operators reacting to takeover interest and rerating risk by checking our curated list of list of solid balance sheet and fundamentals (24 results) built to weather volatile deal cycles.
Surgery Partners now trades near the US$23.50 cash offer, yet still sits below analyst targets. Is the market correctly pricing in execution and balance sheet risks, or leaning too hard into caution?
Most Popular Narrative: 29% Overvalued
The most followed narrative now places Surgery Partners' fair value at about $18.00, which is well below the last close at $23.25. As a result, the going private offer is being weighed against a framework that already viewed the stock as expensive.
Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.
See why 5 investors see Surgery Partners as 29% overvalued .
Result: Fair Value of $17.95 (OVERVALUED)
Still, rising interest costs and slower than planned acquisitions could easily pressure Surgery Partners' margins and keep the analyst narrative under strain.
Find out about the key risks to this Surgery Partners narrative .
Next Steps
Seen enough conflicting views on Surgery Partners to feel unsure about your own stance, yet still want to act before sentiment shifts again? Run through the key red flags yourself and start with the 2 important warning signs .
Looking for more investment ideas beyond Surgery Partners?
If the Surgery Partners story has you rethinking risk, do not stop here. Fresh ideas often come from looking where others are not paying attention.
-
Target income resilience by reviewing companies that appear on our 5 dividend fortresses and see which payouts might better match your cash flow goals.
-
Hunt for quality at a discount by checking the 21 high quality undiscovered gems before other investors start paying attention to the same opportunities.
-
Dial back portfolio stress by scanning the 30 resilient stocks with low risk scores and compare those lower risk profiles with what you currently hold.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SGRY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
